EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR
Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Allergy |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/falgy.2024.1531788/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548176750444544 |
|---|---|
| author | G. K. Scadding D. M. Conti D. M. Conti S. Scheire V. Backer M. Blaiss L. O. Cardell L. O. Cardell W. De Yun A. K. Ellis W. Fokkens A. T. Fox T. Gilbert Kruz S. Halken P. W. Hellings P. W. Hellings P. W. Hellings V. Hox L. Kalogjera S. Lau S. Marinho M. McDonald R. Mösges R. Mösges J. Mullol S. Nasser R. Pawankar D. Price D. Price D. Ryan G. Scadding P. Smith M. Sosa Kostrábová M. Vazquez-Ortiz U. Wahn L. Zhang P. Gevaert |
| author_facet | G. K. Scadding D. M. Conti D. M. Conti S. Scheire V. Backer M. Blaiss L. O. Cardell L. O. Cardell W. De Yun A. K. Ellis W. Fokkens A. T. Fox T. Gilbert Kruz S. Halken P. W. Hellings P. W. Hellings P. W. Hellings V. Hox L. Kalogjera S. Lau S. Marinho M. McDonald R. Mösges R. Mösges J. Mullol S. Nasser R. Pawankar D. Price D. Price D. Ryan G. Scadding P. Smith M. Sosa Kostrábová M. Vazquez-Ortiz U. Wahn L. Zhang P. Gevaert |
| author_sort | G. K. Scadding |
| collection | DOAJ |
| description | Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention. |
| format | Article |
| id | doaj-art-2847b79b59314987ad6173bc7fdf128d |
| institution | Kabale University |
| issn | 2673-6101 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Allergy |
| spelling | doaj-art-2847b79b59314987ad6173bc7fdf128d2025-02-03T06:33:45ZengFrontiers Media S.A.Frontiers in Allergy2673-61012025-02-01510.3389/falgy.2024.15317881531788EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in ARG. K. Scadding0D. M. Conti1D. M. Conti2S. Scheire3V. Backer4M. Blaiss5L. O. Cardell6L. O. Cardell7W. De Yun8A. K. Ellis9W. Fokkens10A. T. Fox11T. Gilbert Kruz12S. Halken13P. W. Hellings14P. W. Hellings15P. W. Hellings16V. Hox17L. Kalogjera18S. Lau19S. Marinho20M. McDonald21R. Mösges22R. Mösges23J. Mullol24S. Nasser25R. Pawankar26D. Price27D. Price28D. Ryan29G. Scadding30P. Smith31M. Sosa Kostrábová32M. Vazquez-Ortiz33U. Wahn34L. Zhang35P. Gevaert36Royal National ENT Hospital and University College, London, United KingdomEscuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, SpainAllergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, BelgiumUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, BelgiumDepartment of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, DenmarkMedical College of Georgia at Augusta University, Augusta, GA, United StatesDivision of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, SwedenDepartment of ENT Diseases, Karolinska University Hospital, Stockholm, SwedenDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore0Division of Allergy & Immunology, Department of Medicine, Queen’s University, Kingston, ON, Canada1Department of Otorhinolaryngology, Amsterdam University Medical Centres, Amsterdam, Netherlands2Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom3Patient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium4Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, DenmarkEscuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, no. 2, Ciudad Universitaria de Cantoblanco, Madrid, Spain5Laboratory of Upper Airways Research, Department of Otorhinolaryngology, University of Ghent, Ghent, Belgium6Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium7Department of Otorhinolaryngology, Cliniques Universitaires Saint Luc, Brussels, Belgium8Department of Otorhinolaryngology/Head and Neck Surgery, University Hospital Centre “Sestre milosrdnice”, Zagreb School of Medicine, Zagreb, Croatia9Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany0Allergy Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom1The Allergy Clinic, Johannesburg, South Africa2ClinCompetence Cologne GmbH, Cologne, Germany3Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany4Rhinology Unit & Smell Clínic, Department of Otorhinolaryngology, Hospital Clínic Barcelona, Universitat de Barcelona; FRCB-IDIBAPS; CIBERES, Barcelona, Catalonia, Spain5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom6Department of Pediatrics, Nippon Medical School, Bunkyo-ku, Tokyo, Japan7Observational and Pragmatic Research Institute, Singapore, Singapore8Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom9Usher Institute, University of Edinburgh, Edinburgh, Scotland0Allergy Department, Royal Brompton Hospital, London, United Kingdom1Griffth University, Southport, QLD, Australia3Patient Advisory Board, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium2Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom3Charite University Medicine, Berlin, Germany4Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, ChinaUpper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, BelgiumAllergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- diagnosed, suboptimally treated and poorly controlled. In the light of new knowledge and treatment options, there is a necessity to update or revise fundamental AR definitions to facilitate communication across diverse specialties engaged in its treatment and to improve patient care. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) convened a meeting of experts and patient representatives to deliberate the optimal methodology for measuring AR treatment responses and establishing novel treatment goals. This paper presents a consensus on revised AR definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory severe allergic rhinoconjunctivitis (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat to target, relapse, progression, disease modification, and prevention.https://www.frontiersin.org/articles/10.3389/falgy.2024.1531788/fullallergic rhinitisquality of lifedefinitionssevere allergic rhinoconjunctivitis (SARC)refractory severe allergic rhinoconjunctivitis (R-SARC)biologics |
| spellingShingle | G. K. Scadding D. M. Conti D. M. Conti S. Scheire V. Backer M. Blaiss L. O. Cardell L. O. Cardell W. De Yun A. K. Ellis W. Fokkens A. T. Fox T. Gilbert Kruz S. Halken P. W. Hellings P. W. Hellings P. W. Hellings V. Hox L. Kalogjera S. Lau S. Marinho M. McDonald R. Mösges R. Mösges J. Mullol S. Nasser R. Pawankar D. Price D. Price D. Ryan G. Scadding P. Smith M. Sosa Kostrábová M. Vazquez-Ortiz U. Wahn L. Zhang P. Gevaert EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR Frontiers in Allergy allergic rhinitis quality of life definitions severe allergic rhinoconjunctivitis (SARC) refractory severe allergic rhinoconjunctivitis (R-SARC) biologics |
| title | EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR |
| title_full | EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR |
| title_fullStr | EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR |
| title_full_unstemmed | EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR |
| title_short | EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR |
| title_sort | euforea meeting on defining disease states in allergic rhinitis towards a unified language in ar |
| topic | allergic rhinitis quality of life definitions severe allergic rhinoconjunctivitis (SARC) refractory severe allergic rhinoconjunctivitis (R-SARC) biologics |
| url | https://www.frontiersin.org/articles/10.3389/falgy.2024.1531788/full |
| work_keys_str_mv | AT gkscadding euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT dmconti euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT dmconti euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT sscheire euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT vbacker euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT mblaiss euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT locardell euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT locardell euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT wdeyun euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT akellis euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT wfokkens euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT atfox euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT tgilbertkruz euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT shalken euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT pwhellings euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT pwhellings euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT pwhellings euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT vhox euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT lkalogjera euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT slau euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT smarinho euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT mmcdonald euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT rmosges euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT rmosges euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT jmullol euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT snasser euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT rpawankar euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT dprice euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT dprice euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT dryan euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT gscadding euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT psmith euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT msosakostrabova euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT mvazquezortiz euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT uwahn euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT lzhang euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar AT pgevaert euforeameetingondefiningdiseasestatesinallergicrhinitistowardsaunifiedlanguageinar |